Chapters Transcript Video Marlise Luskin, MD, MSCE discusses results of a phase 1 trial Venetoclax plus inotuzumab ozogramicin for relapsed and refractory ALL: Results of a phase 1 trial We're really excited by this study, uh, because, uh, this is a high-risk disease. When, uh, BAL relapses, uh, fortunately, we do have, uh, more effective therapies than we used to have. Inattuzumab, ozoomycin is an anti-CD22 antibody drug conjugate that does have high response rates, uh, in patients with relapsed BALL. However, uh, patients who get that treatment, uh, the depths and the duration of the response is, uh, is less than 6 months, and so we've been interested in trying to improve the outcomes of patients receiving this drug. Based on pre-clinical data suggesting potential synergy between venetalax, which is a BCL-2 inhibitor, and inatuzumab, we designed a study looking at the addition of venetalax to the standard of care inatuzumab regimen to look at the uh safety, tolerability, and efficacy of this combination. And those are the results we're presenting at AS this year. We're really uh excited to, to, uh, to, to demonstrate and show our colleagues uh that this uh drug uh combination of adding venetolax and natuzumab was well tolerated. It was a convenient, uh, schedule with uh weekly infusions of vinatuzumab and an oral regimen of venetoclax. The majority. of patients could be treated outpatients without any, uh, any concerning safety, and we are able to show that the response rates are high with the majority of patients able to bridge to allogeneic stem cell transplant with the goal of a durable remission. So we're really excited to offer this promising regimen to our colleagues and to see this, uh, this research continue to benefit all of our patients. Published December 18, 2025 Created by Related Presenters Marlise Luskin, MD, MSCE Medical Oncology View full profile
